Overview
Generate Platform combining generative AI with large-scale biological experimentation to design protein therapeutics, including clinical-stage programs GB-0895 (anti-TSLP), GB-0669, and partnered assets with Amgen and Novartis.
Product and company
Generate Platform is a verified product offering linked to the Brel Digital company profile for Generate Biomedicines.
Use cases
Generate Platform combining generative AI with large-scale biological experimentation to design protein therapeutics, including clinical-stage programs GB-0895 (anti-TSLP), GB-0669, and partnered assets with Amgen and Novartis.
Target customer
Internal pipeline teams, pharmaceutical partners, and Flagship Pioneering portfolio collaborators seeking AI-generated biologics across immunology, oncology, and infectious disease.
Technologies
Primary technologies assigned from the linked company profile: Deep Learning, Generative AI, Healthcare Analytics, Machine Learning, Predictive Analytics.
Sources and references
- Official product / company source: https://generatebiomedicines.com/media-center/generatebiomedicines-to-initiate-global-phase-3-studies-of-gb-0895-a-long-acting-anti-tslp-antibody-for-severe-asthma-engineered-with-ai
- Supporting source: https://investors.generatebiomedicines.com/leadership-team/
Product facts are limited to information already verified on the linked Brel company profile and its cited official URLs. No speculative capabilities are added.
Last reviewed
This product profile was last reviewed on 2026-07-14.
Correction request
If this product record is inaccurate or outdated, submit a correction through Brel Digital’s Corrections Policy.
Features and capabilities
- Generate Platform combining generative AI with large-scale biological experimentation to design protein therapeutics, inc
- including clinical-stage programs GB-0895 (anti-TSLP)
- and partnered assets with Amgen
- Novartis
Extracted from the linked company product description already verified on Brel. No capabilities were invented.